Why psychiatry needs better patient outcome data on medical cannabis
Dr Imogen Kretzschmar, consultant psychiatrist at Mamedica, examines medical cannabis's mental health benefits for patients under specialist supervision. Dr Imogen Kretzschmar, …
Post
-
-
ConcertAI enhances CancerLinQ Suite for oncology trials
ConcertAI has announced enhancements to its CancerLinQ Suite, incorporating AI-driven trial matching and contextualised patient insights. These updates aim to support …
-
GSK’s hepatitis B drug touts functional curative potential in double Phase III win
GSK and Ionis Pharmaceuticals’ genetic medicine, bepirovirsen, has demonstrated its functional curative potential in chronic hepatitis B (CHB) – a …
-
Kalohexis doses first patients in 710GO Phase I trial for obesity
Kalohexis has dosed the first patients in its Phase I first-in-human clinical trial of 710GO, an oral dual melanocortin-3 receptor/melanocortin-4 …
-
Clinical trial experts cite trust and regulatory uncertainty as AI barriers
Half of clinical trial experts asked in a recent survey cited trust and regulatory uncertainty as the major barriers to …
-
Hansa Biopharma’s Idefrix leads to one-year GvHD survival in kidney transplant
Hansa Biopharma’s Idefrix (imlifidase) has seen a 90% one-year survival from graft versus host disease (GvHD) in patients following a …
-
FDA accelerated approval of Hepcludex significant milestone for US HDV market
Gilead Sciences has announced that the US Food and Drug Administration (FDA) has granted accelerated approval to its antiviral, Hepcludex …
-
New malaria vaccine shown to prevent child deaths
The World Health Organization (WHO) published new data this month showing the impact of novel malaria vaccines in children. This …
-
Tryngolza shows efficacy in severe hypertriglyceridemia as approval verdicts loom
Sobi has touted new efficacy results for Tryngolza (olezarsen) in severe hypertriglyceridemia, as the company and its commercial partner, Ionis …
-
MSD and Adcendo sign collaboration agreement for Phase Ib trial
Merck & Co (MSD) and Adcendo have entered a collaboration and supply agreement to evaluate ADCE-T02 with Keytruda (pembrolizumab) in …
-
First participant dosed in Jade’s Phase II JUNIPER trial for IgAN
Jade Biosciences has dosed the first participant in its Phase II JUNIPER clinical trial, evaluating JADE101 for immunoglobulin A nephropathy …
-
How price variation impacts employers
This is the first episode in our second season exploring the evolving landscape of real-world data and its role in …
-
Bial concludes treatment period in Phase IIb ACTIVATE trial for PD
Bial has completed the treatment in its Phase IIb ACTIVATE clinical trial evaluating BIA 28-6156 (pariceract) in Parkinson’s disease (PD) …
-
Lilly’s weight loss pill shows 13% weight loss in adults over 65 years of age
Eli Lilly’s Foundayo (orforglipron) has led to weight loss of 13% in post-hoc analysis of patients aged over 65 from …
-
Hyperfine’s portable MRI system demonstrates time-saving benefit in new data readout
Hyperfine has shared new data demonstrating time-saving advantages for its portable brain MRI system’s integration into emergency department workflows versus …
